MedPath

Mitoxantrone

Generic Name
Mitoxantrone
Drug Type
Small Molecule
Chemical Formula
C22H28N4O6
CAS Number
65271-80-9
Unique Ingredient Identifier
BZ114NVM5P
Background

An anthracenedione-derived antineoplastic agent.

Indication

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
Associated Therapies
Autologous hematopoietic stem cell transplant
Clinical Trials
Related News

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

Phase 1
Completed
Conditions
Recurrent/Refractory Lymphoma
Interventions
First Posted Date
2021-12-30
Last Posted Date
2021-12-30
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
24
Registration Number
NCT05173545
Locations
🇨🇳

Guizhou Cancer Hospita, Guiyang, Guizhou, China

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

Phase 2
Conditions
Advanced Pancreatic Cancer
Interventions
First Posted Date
2021-10-29
Last Posted Date
2021-10-29
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
38
Registration Number
NCT05100329

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Phase 1
Conditions
Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions
First Posted Date
2021-10-29
Last Posted Date
2021-10-29
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
58
Registration Number
NCT05100303
Locations
🇨🇳

The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Phase 2
Suspended
Conditions
Advanced Malignant Tumor
Interventions
First Posted Date
2021-10-22
Last Posted Date
2022-09-10
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
120
Registration Number
NCT05089461
Locations
🇨🇳

the first affiliated hospital of Dalian medical university, Dalian, Liaoning, China

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

First Posted Date
2021-09-22
Last Posted Date
2022-02-01
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
60
Registration Number
NCT05052970
Locations
🇨🇳

Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
First Posted Date
2021-06-16
Last Posted Date
2024-02-23
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
28
Registration Number
NCT04927481
Locations
🇨🇳

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

🇨🇳

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China

🇨🇳

Daqing People's Hospital, Daqing, Helongjiang, China

and more 26 locations

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2021-06-10
Last Posted Date
2024-02-09
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
29
Registration Number
NCT04921878
Locations
🇨🇳

Affiliated Hospital of Hebei University, Baoding, Hebei, China

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

Phase 1
Completed
Conditions
Recurrent Head and Neck Cancer
Metastatic Head and Neck Cancer
Interventions
First Posted Date
2021-05-26
Last Posted Date
2024-03-07
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
45
Registration Number
NCT04902027
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Phase 1
Terminated
Conditions
Unresectable or Metastatic Bone and Soft Tissue Sarcoma
Interventions
First Posted Date
2021-05-25
Last Posted Date
2024-03-07
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
31
Registration Number
NCT04900766
Locations
🇨🇳

Beijing Jishuitan Hospital, Beijing, Beijing, China

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Phase 1
Recruiting
Conditions
Acute Biphenotypic Leukemia
Mixed Phenotype Acute Leukemia
Relapsed Acute Myeloid Leukemia
Relapsed Mixed Phenotype Acute Leukemia
Refractory Acute Myeloid Leukemia
Relapsed Acute Biphenotypic Leukemia
Relapsed Myeloid Neoplasm
Refractory Acute Biphenotypic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Refractory Myeloid Neoplasm
Interventions
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Biospecimen Collection
First Posted Date
2021-03-15
Last Posted Date
2025-05-04
Lead Sponsor
University of Washington
Target Recruit Count
62
Registration Number
NCT04797767
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy